“The data from the ACHIEVE trial in DM1 show substantial functional benefit across a range of clinical measures, and we are excited to have selected the dose for our Registrational Expansion Cohort,” said Doug Kerr, M.D., Ph.D., chief medical officer of Dyne. “DM1 is ...
DELIVER is a Phase 1/2 global clinical trial evaluating DYNE-251, consisting of a 24-week multiple ascending dose (MAD) randomized placebo-controlled period, a 24-week open-label extension and a 96-week long-term extension. The trial, which is designed to be registrational...
The next question about the performance of the proposed model was as follows: Can the advantage be merely for adding a nonlinearity, i.e., could the inclusion of a random nonlinearity term do as well? The comparison with an AE NN model, as a general nonlinear approximator, shows that ...